CREATIVE DESIGN INVESTMENTS, LLC – Trademark Portfolio

Entity Type: 16

CREATIVE DESIGN INVESTMENTS, LLC holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 16 filings in this category. Currently, 8 trademarks are registered and 1 is pending. Notable registered marks include D-ANAOXN, A-ANOLONE, WINNIDROL, CLENTRIMIX, and TESTOSTEROXN. The owner is based in TRAVERSE CITY, MI.

2460 NEAH TA WANTA

TRAVERSE CITY, MI 49686

16 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CREATIVE DESIGN INVESTMENTS, LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (16 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does CREATIVE DESIGN INVESTMENTS, LLC have?

CREATIVE DESIGN INVESTMENTS, LLC has 16 U.S. trademarks filed with the USPTO. Of these, 8 registered, 1 pending, 1 abandoned, 6 cancelled.

What trademark classes does CREATIVE DESIGN INVESTMENTS, LLC file in?

CREATIVE DESIGN INVESTMENTS, LLC files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are CREATIVE DESIGN INVESTMENTS, LLC's most well-known trademarks?

CREATIVE DESIGN INVESTMENTS, LLC's registered trademark portfolio includes well-known marks such as D-ANAOXN, A-ANOLONE, WINNIDROL, CLENTRIMIX, and TESTOSTEROXN. These are among 8 currently registered trademarks in the portfolio.

What is CREATIVE DESIGN INVESTMENTS, LLC's trademark registration success rate?

CREATIVE DESIGN INVESTMENTS, LLC has a 53% trademark registration rate, with 8 out of 15 resolved applications resulting in successful registration. Currently, 1 application is pending review.